vs
Side-by-side financial comparison of FIBROGEN INC (KYNB) and TAT TECHNOLOGIES LTD (TATT). Click either name above to swap in a different company.
TAT TECHNOLOGIES LTD is the larger business by last-quarter revenue ($46.2M vs $25.4M, roughly 1.8× FIBROGEN INC). TAT TECHNOLOGIES LTD runs the higher net margin — 10.5% vs -129.8%, a 140.3% gap on every dollar of revenue. TAT TECHNOLOGIES LTD produced more free cash flow last quarter ($4.8M vs $-59.3M).
FibroGen Inc. is a biopharmaceutical firm developing and commercializing innovative therapies for unmet medical needs, targeting fibrotic diseases, anemia and cancer. Its lead product roxadustat is approved in multiple markets including China and Japan, serving patients across key therapeutic segments.
TAT Technologies Ltd. is a publicly traded company, headquartered in the United States, providing environmental control products and services for the commercial and military aviation industries. Its shares are traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange.
KYNB vs TATT — Head-to-Head
Income Statement — Q1 FY2024 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $25.4M | $46.2M |
| Net Profit | $-32.9M | $4.8M |
| Gross Margin | 15.9% | 25.1% |
| Operating Margin | -193.9% | 11.4% |
| Net Margin | -129.8% | 10.5% |
| Revenue YoY | -29.9% | — |
| Net Profit YoY | 57.1% | — |
| EPS (diluted) | $-0.33 | $0.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $46.2M | ||
| Q2 25 | — | $43.1M | ||
| Q1 24 | $25.4M | — | ||
| Q4 23 | $-73.8M | — | ||
| Q3 23 | $40.1M | — | ||
| Q2 23 | $44.3M | — | ||
| Q1 23 | $36.2M | — | ||
| Q4 22 | $34.4M | — |
| Q3 25 | — | $4.8M | ||
| Q2 25 | — | $3.4M | ||
| Q1 24 | $-32.9M | — | ||
| Q4 23 | $-56.2M | — | ||
| Q3 23 | $-63.6M | — | ||
| Q2 23 | $-87.7M | — | ||
| Q1 23 | $-76.7M | — | ||
| Q4 22 | $-66.2M | — |
| Q3 25 | — | 25.1% | ||
| Q2 25 | — | 25.1% | ||
| Q1 24 | 15.9% | — | ||
| Q4 23 | — | — | ||
| Q3 23 | 89.4% | — | ||
| Q2 23 | 87.1% | — | ||
| Q1 23 | 90.3% | — | ||
| Q4 22 | 85.7% | — |
| Q3 25 | — | 11.4% | ||
| Q2 25 | — | 10.3% | ||
| Q1 24 | -193.9% | — | ||
| Q4 23 | 128.8% | — | ||
| Q3 23 | -158.2% | — | ||
| Q2 23 | -198.7% | — | ||
| Q1 23 | -210.4% | — | ||
| Q4 22 | -192.5% | — |
| Q3 25 | — | 10.5% | ||
| Q2 25 | — | 8.0% | ||
| Q1 24 | -129.8% | — | ||
| Q4 23 | 76.2% | — | ||
| Q3 23 | -158.5% | — | ||
| Q2 23 | -197.8% | — | ||
| Q1 23 | -212.1% | — | ||
| Q4 22 | -192.6% | — |
| Q3 25 | — | $0.37 | ||
| Q2 25 | — | $0.30 | ||
| Q1 24 | $-0.33 | — | ||
| Q4 23 | $-0.56 | — | ||
| Q3 23 | $-0.65 | — | ||
| Q2 23 | $-0.90 | — | ||
| Q1 23 | $-0.81 | — | ||
| Q4 22 | $-0.70 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.6M | $47.1M |
| Total DebtLower is stronger | — | $9.9M |
| Stockholders' EquityBook value | $-228.1M | $170.7M |
| Total Assets | $365.9M | $224.1M |
| Debt / EquityLower = less leverage | — | 0.06× |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $47.1M | ||
| Q2 25 | — | $43.1M | ||
| Q1 24 | $177.6M | — | ||
| Q4 23 | $203.5M | — | ||
| Q3 23 | $251.3M | — | ||
| Q2 23 | $335.7M | — | ||
| Q1 23 | $355.9M | — | ||
| Q4 22 | $422.0M | — |
| Q3 25 | — | $9.9M | ||
| Q2 25 | — | $10.3M | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — |
| Q3 25 | — | $170.7M | ||
| Q2 25 | — | $165.8M | ||
| Q1 24 | $-228.1M | — | ||
| Q4 23 | $-204.2M | — | ||
| Q3 23 | $-157.2M | — | ||
| Q2 23 | $-102.3M | — | ||
| Q1 23 | $-48.9M | — | ||
| Q4 22 | $-21.4M | — |
| Q3 25 | — | $224.1M | ||
| Q2 25 | — | $213.6M | ||
| Q1 24 | $365.9M | — | ||
| Q4 23 | $423.5M | — | ||
| Q3 23 | $460.4M | — | ||
| Q2 23 | $515.1M | — | ||
| Q1 23 | $538.5M | — | ||
| Q4 22 | $610.1M | — |
| Q3 25 | — | 0.06× | ||
| Q2 25 | — | 0.06× | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-59.3M | $7.5M |
| Free Cash FlowOCF − Capex | $-59.3M | $4.8M |
| FCF MarginFCF / Revenue | -233.9% | 10.3% |
| Capex IntensityCapex / Revenue | 0.1% | 5.9% |
| Cash ConversionOCF / Net Profit | — | 1.55× |
| TTM Free Cash FlowTrailing 4 quarters | $-274.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $7.5M | ||
| Q2 25 | — | $6.9M | ||
| Q1 24 | $-59.3M | — | ||
| Q4 23 | $-18.3M | — | ||
| Q3 23 | $-84.5M | — | ||
| Q2 23 | $-110.6M | — | ||
| Q1 23 | $-101.6M | — | ||
| Q4 22 | $-52.5M | — |
| Q3 25 | — | $4.8M | ||
| Q2 25 | — | $3.6M | ||
| Q1 24 | $-59.3M | — | ||
| Q4 23 | $-18.6M | — | ||
| Q3 23 | $-85.2M | — | ||
| Q2 23 | $-111.6M | — | ||
| Q1 23 | $-102.2M | — | ||
| Q4 22 | $-52.8M | — |
| Q3 25 | — | 10.3% | ||
| Q2 25 | — | 8.5% | ||
| Q1 24 | -233.9% | — | ||
| Q4 23 | 25.2% | — | ||
| Q3 23 | -212.3% | — | ||
| Q2 23 | -251.7% | — | ||
| Q1 23 | -282.6% | — | ||
| Q4 22 | -153.8% | — |
| Q3 25 | — | 5.9% | ||
| Q2 25 | — | 7.7% | ||
| Q1 24 | 0.1% | — | ||
| Q4 23 | -0.3% | — | ||
| Q3 23 | 1.7% | — | ||
| Q2 23 | 2.2% | — | ||
| Q1 23 | 1.6% | — | ||
| Q4 22 | 1.0% | — |
| Q3 25 | — | 1.55× | ||
| Q2 25 | — | 2.02× | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KYNB
| Drug Product Revenue | $24.5M | 97% |
| Other | $878.0K | 3% |
TATT
Segment breakdown not available.
